Does Finasteride Cause Man Boobs?

Does finasteride cause man boobs? Yes, gynaecomastia (enlarged breast tissue in men) is listed as an uncommon side effect of finasteride in the UK Summary of Product Characteristics for both the 1 mg and 5 mg formulations. Finasteride works by reducing dihydrotestosterone (DHT), which shifts the balance between androgens and oestrogens, potentially stimulating breast tissue growth in some men. This article explains how common this side effect is, what symptoms to watch for, what to do if breast changes occur, and what alternatives are available to discuss with your GP.

Can finasteride really cause man boobs?

Yes, finasteride can cause gynaecomastia by reducing DHT and increasing relative oestrogenic activity; it is listed as an uncommon adverse effect in the UK SmPC for both the 1 mg and 5 mg formulations.

Finasteride can cause gynaecomastia (the medical term for enlarged breast tissue in men), and this is listed as an uncommon side effect in the UK Summary of Product Characteristics (SmPC) for both finasteride 1 mg (used for male pattern hair loss) and finasteride 5 mg (used for benign prostatic hyperplasia). Finasteride works by inhibiting the enzyme 5-alpha reductase, which converts testosterone into dihydrotestosterone (DHT).^[20][1] By reducing DHT levels, finasteride alters the balance between androgens and oestrogens in the body. Since oestrogens stimulate breast tissue growth, a relative increase in oestrogenic activity compared to androgenic activity can, in some men, lead to breast tissue enlargement or tenderness.

The UK SmPCs for both strengths list gynaecomastia and breast tenderness as recognised adverse effects, reflecting clinical trial and post-marketing data reviewed by the MHRA at the time of authorisation. The NHS medicines page for finasteride also acknowledges breast changes as a known side effect. This means gynaecomastia caused by finasteride is a genuine pharmacological effect rather than a myth or exaggeration.

The mechanism does not mean every man taking finasteride will develop breast changes. Individual hormonal sensitivity varies considerably, and many men complete long courses of finasteride without experiencing any breast-related symptoms. However, the possibility is real enough that patients and prescribers should be aware of it before starting treatment, and any breast changes that develop during treatment should be assessed promptly by a healthcare professional.

How common is gynaecomastia with finasteride in the UK?

Gynaecomastia is classified as uncommon, estimated to affect 1 in 100 to 1 in 1,000 finasteride users, with both breast tenderness and breast enlargement listed separately in UK prescribing information.

Gynaecomastia is classified as an uncommon side effect of finasteride in the UK SmPCs for both the 1 mg and 5 mg formulations. Under standard EU/UK frequency definitions, "uncommon" means it is estimated to affect between 1 in 100 and 1 in 1,000 users. Breast tenderness and breast enlargement are both listed separately in the adverse reactions tables of the relevant SmPCs, and either or both may occur.^[1][2]

In clinical trials for finasteride 1 mg (used for androgenetic alopecia) and finasteride 5 mg (used for benign prostatic hyperplasia), breast-related events were reported in a small proportion of participants. Post-marketing experience may reflect a broader population than controlled trials, which often exclude men with pre-existing hormonal conditions that could increase susceptibility; however, no UK pharmacovigilance source has quantified a specific post-marketing rate, and this article does not claim one.

It is also important to distinguish true gynaecomastia (glandular breast tissue enlargement, which feels firm and is centred beneath the nipple) from pseudogynaecomastia (fatty tissue deposition across the chest, common in men who are overweight). A GP can differentiate between these on examination, and the distinction matters because pseudogynaecomastia is not caused by finasteride and does not resolve with stopping the drug.

Gynaecomastia also has multiple causes unrelated to finasteride, including obesity, alcohol use, other medications (such as spironolactone, some antifungals and certain antipsychotics), and natural hormonal fluctuations. Age-related hormonal changes are particularly common in older men and can coincide with finasteride use without being caused by it. A GP can help distinguish drug-induced gynaecomastia from other causes through history-taking and, where appropriate, blood tests.

What side effects should you watch for, and when to get help?

Watch for breast tenderness, swelling or firmness beneath the nipple, and nipple discharge; contact your GP if these occur, and seek urgent help for mood changes, allergic reactions or thoughts of self-harm.

The most relevant breast-related symptoms to monitor while taking finasteride include breast tenderness or pain, noticeable swelling or firmness beneath one or both nipples, and any nipple discharge. These symptoms may appear gradually or relatively quickly after starting treatment or after a dose change. The UK SmPC advises that patients who notice gynaecomastia or breast tenderness should inform their doctor.

Beyond breast changes, finasteride carries other recognised side effects that patients should be aware of:

• Sexual side effects: Reduced libido, erectile dysfunction and ejaculation disorders are listed in the SmPC. Some men report that these persist after stopping the drug, a phenomenon sometimes called post-finasteride syndrome, though the evidence base for this as a defined clinical entity remains under review.

• Mood changes: Depression and, rarely, suicidal ideation have been reported in post-marketing data, and the MHRA has updated finasteride labelling to reflect this.^[9][10] In line with MHRA advice, if you develop depression or thoughts of self-harm or suicide while taking finasteride, stop the medication and seek medical help promptly by contacting your GP or, outside of surgery hours, NHS 111. If you are in immediate danger, call 999.

• Allergic reactions: Rash, urticaria, swelling of the lips or face, and anaphylaxis have been reported rarely. A severe allergic reaction (such as throat swelling or difficulty breathing) requires an immediate 999 call.

For breast swelling, tenderness or nipple discharge, contact your GP at any point during treatment. Suspected side effects from finasteride can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What can you do if you notice breast changes on finasteride?

Contact your GP rather than stopping finasteride abruptly; they will assess whether changes are drug-induced, check for red flag features, and advise on stopping treatment, referral or further investigation.

If you notice breast swelling, tenderness or any nipple discharge while taking finasteride, the first step is to contact your GP rather than stopping the medication abruptly without advice. Your GP will take a clinical history, examine the affected area and consider whether the changes are consistent with drug-induced gynaecomastia or whether another cause needs to be investigated.

It is particularly important not to ignore certain features that may indicate a more serious cause. Red flags that warrant prompt GP assessment include a hard or irregular lump, skin changes over the breast (such as dimpling or puckering), changes to the nipple (such as inversion or bloody discharge), or swollen lymph nodes in the armpit. Male breast cancer is rare but does occur, and NICE guidance (NG12: Suspected cancer: recognition and referral) supports urgent referral via a two-week-wait pathway when such features are present. Your GP will advise on whether urgent referral is needed.

Depending on the assessment, your GP may recommend one or more of the following approaches:

• Watchful waiting: If the changes are mild and not causing significant discomfort, monitoring over a few weeks may be appropriate, especially if you have only recently started finasteride. Recent gynaecomastia is more likely to regress after stopping the drug than long-standing changes, where breast tissue may have become fibrotic.

• Stopping or switching treatment: If finasteride is judged to be the likely cause and the symptoms are troublesome, your GP may advise discontinuing it.

• Referral: If the diagnosis is uncertain, or if breast changes persist after stopping finasteride, your GP may refer you to an endocrinologist or a breast clinic for further investigation, which could include blood tests (measuring testosterone, oestradiol, LH, FSH and prolactin) and imaging.

• Treatment of persistent gynaecomastia: In cases where breast tissue does not resolve, options such as tamoxifen (used off-label and under specialist supervision) or surgical correction may be discussed by a specialist.

Do not purchase medications online to self-treat breast changes without a proper diagnosis.

Are there alternatives to finasteride worth discussing with your GP?

For hair loss, topical minoxidil is an established alternative without hormonal effects; for BPH, alpha-blockers such as tamsulosin do not carry the same hormonal side effect profile as finasteride.

Several alternatives to finasteride exist for the conditions it is used to treat, and discussing these with your GP is a reasonable step if you are concerned about side effects, including gynaecomastia. The right alternative depends on whether you are using finasteride for male pattern hair loss or for benign prostatic hyperplasia (BPH), as the options differ between these indications.

For male pattern hair loss:

• Minoxidil (topical or oral): Minoxidil is a well-established treatment for androgenetic alopecia that works through a different mechanism (vasodilation and prolongation of the hair growth cycle) and does not carry the same hormonal side effect profile as finasteride. Topical minoxidil is available over the counter in the UK. Oral minoxidil is used off-label in the UK for hair loss; a prescriber can advise on its suitability and risks.^[6]

• Dutasteride: Another 5-alpha reductase inhibitor, dutasteride inhibits both type 1 and type 2 isoenzymes (finasteride inhibits only type 2). It is not licensed in the UK for hair loss but is sometimes used off-label.^[11][16] Because it more completely suppresses DHT, it may carry a similar or greater risk of hormonal side effects including gynaecomastia, though direct comparative data are limited; a prescriber can discuss this in the context of your individual circumstances.

• Low-level laser therapy and hair transplant surgery are non-pharmacological options some men consider.

For BPH:

• Alpha-blockers (such as tamsulosin or alfuzosin) relax smooth muscle in the prostate and bladder neck and do not carry the same hormonal effects as finasteride.^[14][15]

• Combination therapy or watchful waiting may be appropriate depending on symptom severity. NICE guidance on lower urinary tract symptoms in men (currently published as NICE guideline NG123, though you should check the NICE website for the most current version) should inform any treatment decision.

Online consultations, such as those offered by Bolt Pharmacy, a GPhC-registered UK online pharmacy, can provide prescriber review for hair loss treatments, with a medicine only recommended where it is clinically appropriate after assessment. Your GP remains the most appropriate starting point for BPH management.

Scientific References

1. Finasteride 5mg Tablets – Summary of Product Characteristics.
2. Finasteride 1mg Tablets – Summary of Product Characteristics.
3. Finasteride 1mg Film-Coated Tablets – Summary of Product Characteristics.
4. Side effects of finasteride.
5. Common questions about finasteride.
6. Finasteride – BNF.
7. Section 4.8: Undesirable effects – frequency definitions.
8. Adverse reactions to drugs – BNF.
9. Finasteride: rare reports of depression and suicidal thoughts.
10. Finasteride and dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction.
11. MHRA strengthens safety warnings for finasteride and dutasteride.
12. Suspected cancer: recognition and referral (NG12).
13. Lower urinary tract symptoms in men: management (CG97).
14. Lower urinary tract symptoms in males – BNF treatment summary.
15. About tamsulosin.
16. Dutasteride in androgenetic alopecia: an update. Current Clinical Pharmacology.
17. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review. BMC Medicine.
18. Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie und Onkologie.
19. Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials. Journal of Endocrinological Investigation.
20. Novel 5α-reductase inhibitors unlinked to depression-like phenotypes in rat model of BPH. The Journal of Steroid Biochemistry and Molecular Biology.

Frequently Asked Questions